Antony Cherukara, Vice PresidentStrategy and Head, Agri-business, was one of the eminent speakers at the 4th edition of the Rural Strategy Summit, organised by The Economic Times .
For more details visit - https://kmwagri.com/news/mr-antony-cherukara-speaks-at-rural-strategy-summit/
Looking for a Pathophysiology Test Bank or solution manuals for practice more questions?
Visit Testmango.com and get your test banks and solution manuals at discount.
Latest 2016 Understanding Pathophysiology, 6th Edition, Latest 2009 Pathophysiology, 4th Edition, 2008 Understanding Pathophysiology, 4th Edition Study Aid and much more available at discount.
Visit us to review all.
To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this link Key InclusionsA detailed assessment of the current market landscape of endocannabinoid system targeted therapeutics, providing information on phase of development (clinical, preclinical, and discovery stage) of lead candidates, target therapeutic area (s), route of administration (oral, topical, sublingual, oromucosal, inhalation and others), dosing frequency (once daily, twice daily, thrice daily and others) and target receptor (CB1, CB2, TRPV-1 and others).
Additionally, the chapter includes information on drug developer(s), including information on year of establishment, company size, and location of headquarters.Elaborate profiles of prominent endocannabinoid system targeted therapeutics developers that are engaged in the development of at least four development programs.
Each profile features a brief overview of the company, its financial information (if available), product portfolio and an informed future outlook.An in-depth analysis of nearly 600 grants that have been awarded to research institutes engaged in endocannabinoid system targeted projects, in the period between 2016 and 2020 (till January), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute centre, funding institute centre, support period, type of grant application, purpose of grant award, grant mechanism, responsible study section, prominent program officers, and type of recipient organizations.An analysis of the partnerships that have been established in the recent past, covering acquisitions, licensing agreements, product development and commercialization agreements, research agreements, clinical trial agreements, joint venture agreements and other relevant types of deals.A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2016-2020, based on parameters, such as year of acquisition, type of acquisition, geographical location of the acquirer and the acquired company, key value drivers, and financial details of the deal (if available).
In addition, the chapter evaluates the deal multiples of acquisitions specifically focused on endocannabinoid system targeted therapeutics, analysing them based on a number of parameters, namely annual revenues, number of employees and experience of the acquired company.
Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals.An insightful chessboard analysis highlighting the most popular drug development strategies / paths adopted by various drug developers (with clinical candidates) in order to progress their lead drug candidates.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:Target Disease IndicationCancerGenetic DisordersNeurological IndicationsOthers Route of AdministrationOralInhalation Key GeographiesNorth AmericaEuropeAsia-Pacific and the Rest of the World To request sample pages, please visit this link Key Questions AnsweredWho are the leading industry players in this market?What are the key clinical conditions addressed by endocannabinoid system targeted therapeutics?What are the biological receptors targeted by cannabinoid-based therapies?What are the factors that are likely to influence the evolution of this market?What are the initiatives undertaken by start-ups and big pharma players engaged in this domain?What kind of partnership models are commonly adopted by stakeholders in this industry?How is the current and future market opportunity likely to be distributed across key market segments?
Kamagra Gold ( Sildenafil ) relaxes the smooth muscles present in the wall of blood vessels and helps in increasing the flow of blood in certain specific areas of the body.
It is used for the treatment of erection disorders and Pulmonary Hypertensionhttps://rxpharmamart.com/product/kamagra-gold/
(Albany, US) DelveInsight has launched a new report on Oral Mucositis Market Insights, Epidemiology and Market Forecast-2030DelveInsight’s “Oral Mucositis (OM) - Market Insights, Epidemiology and Market Forecast - 2030” report provides an overview of the disease and market size of Oral Mucositis for the 7MM major pharmaceutical markets, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
This report covers the various treatment practices, and Oral Mucositis forecasted epidemiology from 2020 to 2030, segmented by the 7 major markets.Some of the key facts of the Report:In 2017, US had the maximum number of incident cases of the total incident cases followed by Japan.Grade 3 or 4 Oral Mucositis occurs in around 85% of patients receiving high-dose radiotherapy.In 2017, the incident population of Oral Mucositis in the United States was 1,956,351.
)Oral Mucositis market report provides insights on the current and emerging therapies.
Oral Mucositis market report offers a global historical and forecasted market covering drug outreach in 7 MM.Oral Mucositis market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Malignant Mesothelioma market.Request for Sample Pages : https://www.delveinsight.com/sample-request/oral-mucositis-om-market“According to Delveinsight, females appear to be more likely than males to develop Oral mucositis.”View Report: https://www.delveinsight.com/report-store/oral-mucositis-om-marketOral Mucositis (OM) is the most common, debilitating complication of cancer chemotherapy and radiotherapy.
It is characterized by inflammation and ulceration in the oral cavity caused by the chemotherapeutic drug substances and radiotherapy used in cancer treatment.
The early symptoms include erythema and light discoloration of the mucosa.
Vyas Giannetti Creative is a leading branding & design agency in Mumbai, India, helping businesses to build their unbeatable brand identity from scratch.
With over 25 years of experience, VGC has helped almost 100+ leading brands.
As of 2019-20, VGC is ranked as one of India’s top design specialists by The Economic Times.For more Visit: Branding Agency in Mumbai